Dr. Mamounas on Selecting Patients With Breast Cancer for Neoadjuvant Chemotherapy

Eleftherios P. Mamounas, MD
Published: Thursday, Oct 23, 2014

Eleftherios Mamounas, MD, MPH, medical director, Comprehensive Breast Program, University of Florida Health Cancer Center, discusses the need to select patients for neoadjuvant chemotherapy.

There are breast cancer subtypes that respond very well to neoadjuvant chemotherapy: triple-negative, HER2-positive, and ER-positive. Once a pathologic complete response is achieved, the oncologist should be aware of clinical trials that test the concept of less aggressive treatment.

It is important to select patients for neoadjuvant chemotherapy, not only by size or nodal status, but also by subtype.
 
Eleftherios Mamounas, MD, MPH, medical director, Comprehensive Breast Program, University of Florida Health Cancer Center, discusses the need to select patients for neoadjuvant chemotherapy.

There are breast cancer subtypes that respond very well to neoadjuvant chemotherapy: triple-negative, HER2-positive, and ER-positive. Once a pathologic complete response is achieved, the oncologist should be aware of clinical trials that test the concept of less aggressive treatment.

It is important to select patients for neoadjuvant chemotherapy, not only by size or nodal status, but also by subtype.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x